We focus on innovative biologics and biosimilar programs, addressing unmet
medical needs in oncology, adjuvant chemotherapy, high cholesterol,
autoimmune diseases and ophthalmic drugs. Advanced technology platforms
have been developed in monoclonal antibody (mAb), Antibody-Drug Conjugate
(ADC), fusion protein and polysaccharides.
We are actively seeking business opportunities including oncology, autoimmune
diseases, liver diseases, diabetes, cardiovascular diseases and